allosteric mutant-EGFR inhibitor

in vivo efficacy in osimertinib-resistant xenograft models

from opt. of prev. disclosed EGFR inhibitor

Nat. Cancer

Dana-Farber Cancer Institute, Boston, MA

JBJ-09-063 chemical structure, allosteric mutant-EGFR inhibitor - Dana-Farber Cancer Institute, Boston, MA

Context. JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR L858R-mutant non-small cell lung cancer (NSCLC). Despite the availability…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: